In SURMOUNT-5, adults with obesity without diabetes were randomized to tirzepatide or semaglutide. At 72 weeks the estimated mean weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide.
A randomized active comparison
The result directly compares the regimens tested in that open-label trial. It does not extend to every formulation, population or duration.
How to interpret the evidence
Retatrutide was not one of the randomized interventions. Its evidence comes from its own trials, including the registered direct comparison with tirzepatide.
Give the strongest weight to studies that randomized both treatments within a shared protocol for the clinical question you are asking.